Pharming Story

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;'>PG</div>
PHGUF -- USA Stock  

USD 1.25  0.05  3.85%

Pharming Grp NV is scheduled to announce its earnings tomorrow. As some millenniums are still trying to avoid healthcare space, I will try to digest Pharming Grp NV a little further in order to understand its potential as a viable investment. What exactly are Pharming Grp shareholders getting in May?
Published over a week ago
View all stories for Pharming Grp | View All Stories
Do analysts believe Pharming Grp (OTC:PHGUF) will continue to surge?
Pharming Grp is OVERVALUED at 1.14 per share with modest projections ahead.
We provide trade recommendations to complement the recent expert consensus on Pharming Grp NV. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of Pharming Grp? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

Watch out for price decline

Please consider monitoring Pharming Grp on a daily basis if you are holding a position in it. Pharming Grp is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Pharming Grp stock to be traded above the $1 level to remain listed. If Pharming Grp stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

What is happening with Pharming Grp NV this year

Annual and quarterly reports issued by Pharming Grp NV are formal financial statements that are published yearly and quarterly and sent to Pharming stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Pharming Grp often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Pharming utilizes its cash?

To perform a cash flow analysis of Pharming Grp, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Pharming Grp is receiving and how much cash it distributes out in a given period. The Pharming Grp cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Is Pharming a risky opportunity?

Let's check the volatility. Pharming is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Pharming (OTC:PHGUF) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. purchasing a share of a Pharming Grp stock makes you a part-owner of that company.

Pharming Grp NV Current Consensus

Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering Pharming Grp NV. The Pharming consensus assessment is calculated by taking the average estimates from all of the analysts covering Pharming Grp

Strong Buy
Strong Buy2100.0
Strong Sell00.0

Our take on today Pharming Grp surge

The skewness is down to 0.95 as of today. Pharming Grp NV exhibits very low volatility with skewness of 0.95 and kurtosis of 2.44. However, we advise investors to further study Pharming Grp NV technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Pharming Grp's otc stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Pharming Grp's otc stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Pharming Grp

Although many other companies in the biotechnology industry are either recovering or due for a correction, Pharming may not be as strong as the others in terms of longer-term growth potentials. While some shareholders may not share our view, we believe that right now is not a good time to increase your holdings in Pharming. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Pharming Grp.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Pharming Grp NV. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to